Mitomycin
Back to searchMolecule Structure
Scientific Name
Mitomycin
Description of the Drug
Mitomycin is an antimetabolite used as an adjunct to ab externo (outside approach) eye surgeries for the treatment of glaucoma and used as a chemotherapeutic agent for various malignancies.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00305
http://www.drugbank.ca/drugs/DB00305
Brand Name(s)
Jelmyto, Mitomycin, Mitosol, Mitozytrex, Mutamycin, Mytozytrex
Company Owner(s)
Hong Kong King Friend Industrial Co Ltd, Urogen Pharma Ltd, Hospira Inc, Hikma Pharmaceuticals Usa Inc, Bristol Myers Co, Mobius Therapeutics Llc, Gland Pharma Ltd, Accord Healthcare Inc, Supergen Inc, Bristol Laboratories Inc Div Bristol Myers Co
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
DNA | NUCLEIC-ACID | INHIBITOR | CHEMBL2311221 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL3760 | |||
PharmGKB | PA450524 | |||
Human Metabolome Database | HMDB0014450 | |||
DrugBank | DB00305 | |||
PubChem: Thomson Pharma | 14924490 | 14899962 | ||
PubChem | 5746 | |||
NMRShiftDB | 60022191 | |||
LINCS | LSM-6310 | |||
Nikkaji | J64.512E | |||
BindingDB | 50428658 | |||
EPA CompTox Dashboard | DTXSID2020898 | |||
DrugCentral | 1819 | |||
Metabolights | MTBLC27504 | |||
Brenda | 3150 | 229659 | 151036 | 229660 |
ChemicalBook | CB8456544 | |||
Guide to Pharmacology | 7089 | |||
rxnorm | MITOSOL | MUTAMYCIN | MITOMYCIN | JELMYTO |
KEGG Ligand | C06681 | |||
ChEBI | 27504 | |||
ZINC | ZINC000030726187 |